Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Cognitive Dysfunction in MDD
NCT04466345Phase 2Completed
- Sponsor
- University Health Network
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in major depressive disorder (MDD), sponsored by University Health Network. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04466345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466345.